Potential target antigens for a universal vaccine in epithelial ovarian cancer.
The prognosis of epithelial ovarian cancer (EOC), the primary cause of death from gynaecological malignancies, has only modestly improved over the last decades. Immunotherapeutic treatment using a cocktail of antigens has been proposed as a "universal" vaccine strategy. We determined the expression of tumor antigens in the context of MHC class I expression in 270 primary tumor samples using tissue microarray. Expression of tumor antigens p53, SP17, survivin, WT1, and NY-ESO-1 was observed in 120 (48.0%), 173 (68.9%), 208 (90.0%), 129 (56.3%), and 27 (11.0%) of 270 tumor specimens, respectively. In 93.2% of EOC, at least one of the investigated tumor antigens was (over)expressed. Expression of MHC class I was observed in 78.1% of EOC. In 3 out 4 primary tumors, (over)expression of a tumor antigen combined with MHC class I was observed. These results indicate that a multiepitope vaccine, comprising these antigens, could serve as a universal therapeutic vaccine for the vast majority of ovarian cancer patients.
Vermeij
Renee
R
Department of Gynecological Oncology, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
Daemen
Toos
T
de Bock
Geertruida H
GH
de Graeff
Pauline
P
Leffers
Ninke
N
Lambeck
Annechien
A
ten Hoor
Klaske A
KA
Hollema
Harry
H
van der Zee
Ate G J
AG
Nijman
Hans W
HW
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000951:Antigens, Neoplasm / Q000235:genetics / Q000276:immunology* / Q000378:metabolism*; D000954:Antigens, Surface / Q000276:immunology / Q000378:metabolism; D002148:Calmodulin-Binding Proteins; D019496:Cancer Vaccines / Q000276:immunology*; D002352:Carrier Proteins / Q000276:immunology / Q000378:metabolism; D005260:Female; D015395:Histocompatibility Antigens Class I / Q000378:metabolism*; D006801:Humans; D007167:Immunotherapy; D051034:Inhibitor of Apoptosis Proteins; D008565:Membrane Proteins / Q000276:immunology / Q000378:metabolism; D046228:Microarray Analysis; D008869:Microtubule-Associated Proteins / Q000276:immunology / Q000378:metabolism; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control; D000077022:Survivin; D016159:Tumor Suppressor Protein p53 / Q000276:immunology / Q000378:metabolism; D025721:WT1 Proteins / Q000276:immunology / Q000378:metabolism; D055815:Young Adult
D000951:Antigens, Neoplasm; D000954:Antigens, Surface; C107489:BIRC5 protein, human; C104948:CTAG1B protein, human; D002148:Calmodulin-Binding Proteins; D019496:Cancer Vaccines; D002352:Carrier Proteins; D015395:Histocompatibility Antigens Class I; D051034:Inhibitor of Apoptosis Proteins; D008565:Membrane Proteins; D008869:Microtubule-Associated Proteins; C090172:SPA17 protein, human; D000077022:Survivin; D016159:Tumor Suppressor Protein p53; D025721:WT1 Proteins